Glaxo Group Limited

Smithkline Beecham Corporation

Gerard Martin Paul Giblin

Neil Derek Miller

Mark Patrick Healy

Ann Louise Walker

Andrew McMurtrie Mason

Susan Roomans

Adrian Hall

Miles Stuart Congreve

Alan Naylor

William L Mitchell

Xiao Qing Lewell

David Nigel Hurst

Andrew John Eatherton

Ian Reginald Kilford

Brian Peter Slingsby

Helen Susanne Price

Nicholas Maughan Clayton

David Norton

Mark James Bamford

Simon John Fawcett MacDonald

Alcide Perboni

Graham George Adam Inglis

Mahmood Ahmed

Derek Anthony Demaine

Richard J Coles

Martin Edward Swarbrick

Dean Andrew Rivers

Richard Howard Green

Derek Anthony Rawlings

Andrew Richard Whittington

James Myatt

Steven Michael Foord

Jennifer Margaret Doughty, Legal Representative

Jennifer M Doughty

Susanne Denise Collins

Stephen Edward Shanahan

Haydn Terence Jones

Stephen Vernon Frye

Riccardo Novelli

Andrew Billinton

Rachel Elizabeth Hosking

Tiziana Scoccitti

Rino Antonio Bit

Matthew Russell Johnson

William Leonard Mitchell

The present invention provides compounds of formula (I) or salts thereof: having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders mediated by S1P1 receptors.

Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists

A compound of formula (I) or a pharmaceutically acceptable derivative thereof, wherein, RRR, R, R, R, X and Y are as defined in the specification; a process for preparing such compounds; a pharmaceutical composition comprising such compounds; and the use of such compounds in medicine.

[object Object]

A compound of formula (I) or a pharmaceutically acceptable derivative thereof, wherein, R, R, R, X and Y are as defined in the specification; a process for preparing such compounds; a pharmaceutical composition comprising such compounds; and the use of such compounds in medicine.

Benzoisoindole derivatives for the treatment of pain

The present invention relates to naphthalene derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine.

Benzo [F] isoindoles as EP4 receptor agonists

Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein X, Y, Z, R, R, R, R, R, R, and Rare as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

Pyridine compounds for the treatment of prostaglandin mediated diseases

Naphthalene derivatives

A compound of formula (I) or a pharmaceutically acceptable derivative thereof, wherein Rto R, X, and Y are as defined in the specification; a process for preparing such compounds; a pharmaceutical composition comprising such compounds; and the use of such compounds in medicine.

Benzoisoindole derivatives and their use as EP4 receptor ligands

The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.

Pyrimidine derivatives and their use as CB2 modulators

The present invention relates to novel pyrrolopyridine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.

Pyrrolopyridine derivatives

Compounds of formula (I) or derivatives thereof: wherein A, B, Z, R, R, R, R, R, and Rare as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

Phenyl compounds

Compounds of formula (I) or salts or solvates thereof or physiologically functional derivatives thereof are potent binders at the EP4 receptor and are of use in the treatment or prevention of conditions such as a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.

Indole derivatives

Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, R, R, R, R, Rand n are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

(2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives

Compounds of formula (I) and pharmaceutically acceptable derivatives thereof bind with high affinity to the EP4 receptor and are of use in the treatment or prevention of conditions such as a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.

Benzo (f) insoindol derivatives and their use as ep4 receptor ligands

The present invention relates to a compound of formula (I): corresponding pharmaceutical compositions, preparation processes, and/or methods of using the aforementioned compounds and/or compositions.

Benzo[f]isoindole derivatives with affinity to the EP4 receptor

Compounds of formula (I)and pharmaceutically acceptable derivatives thereof bind with high affinity to the EP4 receptor and are of use in the treatment or prevention of conditions such as a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.

Naphathalene derivatives which bind to the EP4 receptor

Growing community of inventors

Harlow, United Kingdom

Gerard Martin Paul Giblin